CommercialPrior AuthMedium impact
Isotretinoin Products
Blue Cross & Blue Shield of Mississippi·MS · Dermatology, Family Medicine, Internal Medicine +1 more·Medical Policy
We identified it
Jun 20, 2026
Summary
This BCBSMS policy establishes prior authorization requirements for all isotretinoin products (Accutane and generics) used to treat severe acne. Coverage requires documented failure of at least 60 consecutive days of combination therapy with oral antibiotics, topical retinoids, and topical non-retinoids, with a maximum of two courses allowed.
Action Required
Immediately: Update prior authorization workflow for isotretinoin prescriptions (Absorica, Absorica LD, Accutane, Amnesteem, Claravis, Zenatane). Providers must document: 1) Patient age 12+ years, 2) Severe acne diagnosis, 3) Failed 60+ consecutive days of oral antibiotic + topical retinoid + topical non-retinoid combination therapy within past year, 4) No contraindications. Note: Absorica and Absorica LD are NOT covered on any BCBSMS formulary. Maximum approval is 6 months per course, 2 courses total lifetime limit.